Ars Pharmaceuticals Inc

1. 1

   Election of Directors (three Class III nominees

   ManagementBoard: FOR

   Elect three Class III director nominees—Saqib Islam, Phillip Schneider, and Laura Shawver—to serve three-year terms expiring at the 2029 Annual Meeting.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm (Ernst & Young LLP

   ManagementBoard: FOR

   Ratify the Audit Committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote to Approve Executive Compensation (Say-on-Pay

   ManagementBoard: FOR

   Non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement (‘‘say-on-pay’’).

   More detail

   This non-binding management proposal asks stockholders to approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy materials. Management seeks this vote to obtain stockholder input on its pay programs and to validate compensation practices that it argues align executives’ incentives with long-term stockholder value—chiefly via a pay mix that emphasizes variable, at‑risk compensation (performance-based cash bonuses and stock options). The Board and Compensation Committee present the program as pay‑for‑performance, citing target bonus frameworks tied to regulatory, commercial, market access and financial goals, substantial equity linkages that vest over time, and governance features such as an independent compensation consultant and a clawback policy. Because the vote is advisory, the Board retains discretion but states it will consider the outcome when setting future compensation. The proposal is routine in modern governance but is meaningful because it signals investor acceptance or disapproval of how executives are rewarded, particularly given recent commercialization progress and large equity grants disclosed. Passing the proposal would reinforce management’s current approach; a material negative vote would likely prompt enhanced engagement and potential program adjustments. The Board also ties the frequency of future say‑on‑pay votes to Proposal 4; operationally, the Company expects to hold the next say‑on‑pay vote in 2027 if the Board elects annual votes. In evaluating this proposal, sophisticated analysts should weigh the Company’s commercialization milestones and financial performance against the size and structure of equity grants, severance/change‑in‑control protections, and disclosed pay‑alignment mechanisms.

4. 4

   Advisory Vote on Frequency of Future Advisory Stockholder Votes on Executive Compensation (Say-on-Pay Frequency

   ManagementBoard: FOR

   Non-binding advisory vote where stockholders indicate whether future advisory votes on executive compensation should be held every One Year, Two Years, or Three Years; the Board recommends One Year.

   More detail

   This management-sponsored advisory proposal asks stockholders to indicate their preferred frequency—One, Two, or Three Years—for future non-binding advisory votes on executive compensation. The Board recommends an annual (One Year) frequency to obtain regular, timely investor feedback and to enable the Compensation Committee to respond more quickly to shareholder sentiment as the Company progresses through commercialization and executes on growth initiatives. Because the vote is advisory, the Board retains discretion and will consider the outcome alongside other engagement signals; the proxy materials specify that if no frequency receives a majority, the option with the most votes will be considered the preferred frequency. For a sophisticated evaluator, the governance implications hinge on trade-offs: annual votes increase board accountability and investor engagement but may raise administrative costs and increase focus on short-term reactions; multi-year votes can reduce administrative burden but delay direct feedback on compensation changes. The Company’s context—transitioning to a commercial-stage business with sizable equity awards and active investor ownership—supports management’s rationale for more frequent feedback. A plurality or majority favoring an alternative frequency could trigger further engagement but would not bind the Board to change its practices. Analysts should consider investor preferences among the Company’s significant institutional holders, the non-binding nature of the vote, and how the outcome might influence future compensation design and disclosure practices.

Upcoming shareholder meetings at Ars Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Ars Pharmaceuticals Inc 2026 annual meeting?

Ars Pharmaceuticals Inc (SPRY) holds its 2026 annual shareholder meeting on Wednesday, June 24, 2026.

What is the record date for the Ars Pharmaceuticals Inc 2026 meeting?

The record date for the Ars Pharmaceuticals Inc 2026 meeting is Monday, April 27, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Ars Pharmaceuticals Inc's 2026 meeting?

The board is presenting 3 director nominees at the Ars Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Ars Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 4 proposals at the Ars Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.